Oxidative and nitrosative stress markers in patients on hemodialysis and peritoneal dialysis

Blood Purification

Volumn 32, Issue 3, 2011, Pages 202-208

  Köse, Fadime Aydin ^a   Seziş, Meltem ^a   Akçiçek, Fehmi ^a   Pabuççuoǧlu, Aysun ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Chronic renal failure; Hemodialysis; Nitrosative stress; Oxidative stress; Peritoneal dialysis

Indexed keywords

3 NITROTYROSINE; ADVANCED OXIDATION PROTEIN PRODUCT; MYELOPEROXIDASE; THIOL GROUP;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; MALE; NITROSATIVE STRESS; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PEROXIDASE; SULFHYDRYL COMPOUNDS; TYROSINE;

EID: 79960854132     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000328030     Document Type: Article

References (44)

1. Halliwell B: Oxidants and human disease: some new concepts. FASEB J 1987; 1: 358-364. (Pubitemid 18049734)
2. Halliwell B, Gutteridge JM, Cross CE: Free radicals, antioxidants and human disease: Where are we now? J Lab Clin Med 1992; 119: 598-620.
3. Himmelfarb J, McMonagle E: Manifestations of oxidant stress in uremia. Blood Purif 2001; 19: 200-205. (Pubitemid 32041354)
4. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313. (Pubitemid 26166404)
5. Descamps-Latscha B, Drüeke T, Witko-Sarsat V: Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 2001; 14: 193-199. (Pubitemid 33720852)
6. Berlett BS, Stadtman ER: Protein oxidation in aging, disease and oxidative stress. J Biol Chem 1997; 272: 20313-20316. (Pubitemid 27355575)
7. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A: Biomarkers of oxidative damage in human disease. Clin Chem 2006; 52: 601-623.
8. Stadtman ER, Levin RL: Free redical mediated oxidation of free amino acids and amino acid residues in proteins. Amino acids 2003; 25: 207-218. (Pubitemid 38043943)
9. Dean RT, Fu S, Stocker R, Davies MJ: Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997; 324: 1-18. (Pubitemid 27229359)
10. Capeillère-Blandin C, Gausson V, Nguyen AT, Descamps-Latscha B, Drüeke T, Witko-Sarsat V: Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant 2006; 21: 1555-1563. (Pubitemid 43840618)
11. Massy ZA, Stenvinkel P, Drueke TB: The role of oxidative stress in chronic kidney disease. Semin Dial 2009; 22: 405-408.
12. Ward RA, McLeish KR: Oxidant stress in hemodialysis patients: What are the determining factors? Artif Organs 2003; 27: 230-236. (Pubitemid 36423478)
13. Morimoto H, Nakao K, Fukuoka K, Sarai L, Yano A, Kihara T, Fukuda S, Wada J, Makino H: Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in hemodialysis patients. Nephrol Dial Transplant 2005; 20: 2775-2782. (Pubitemid 41672279)
14. Moreno M, Delbosc S, Dupuy A, Canaud B, Cristol JP: Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005; 9: 37-46. (Pubitemid 40932774)
15. Maruyama Y, Lindholm B, Stenvinkel P: Inflammation and oxidative stress in ESRD-the role of myeloperoxidase. J Nephrol 2004; 17: 72-76.
16. Wu CC, Chen JS, Wu WM, Liao TN, Chu P, Lin SH, Chuang CH, Lin YF: Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transpl 2005; 20: 1134-1139. (Pubitemid 40862102)
17. Mayer B, Zitta S, Greilberger J, Holzer H, Reibnegger G, Hermetter A, Oettl K: Effect of hemodialysis on the antioxidative properties of serum. Biochim Biophys Acta 2003; 1638: 267-272. (Pubitemid 37288965)
18. Müller C, Eisanbrand G, Gradinger M, Rath T, Albert FW, Vienken J, Singh R, Farmer PB, Stockis JP, Janzowski C: Effects of hemodialysis, dialyser type and iron infusion on oxidative stress in uremic patients. Free Rad Res 2004; 38: 1093-1100. (Pubitemid 39504344)
19. Rabbani N, Thornalley PJ: Quantitaion of markers of protein damage by glycation, oxidation and nitration in peritoneal dialysis. Perit Dial Int 2009; 29:S51-S56.
20. Ruiz MC, Portero-Otin M, Pamplona R, Requena JR, Prat J, Lafarga MA, Borras M, Bellmunt MJ: Chemical and immunological characterization of oxidative nonenzymatic protein modifications in dilaysis fluids. Perit Dial Int 2002; 23: 23-32. (Pubitemid 36348156)
21. Latcha S, Hong S, Gibbons N, Kohn N, Mattana J: Relation between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis. Nephrol Dial Transplan 2008; 23: 3295-3301.
22. Thornalley PJ: Technological advances in peritoneal dialysis research. Perit Dial Int 2005; 25: 522-533.
23. Yeo WS, Lee SJ, Lee JR, Kim PK: Nitrosative protein tyrosine modifications: biochemistry and functional significance. BMB Rep 2008; 41: 194-203.
24. Peluffo G, Radi R: Biochemistry of tyrosine nitration in cardiovascular pathology. Cardiovasc Res 2007; 75: 291-302. (Pubitemid 46961930)
25. Abello N, Kerstjens HAM, Postma DS, Bischoff R: Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration and proteomics methods for the identifications of tyrosine-nitrated proteins. J Proteome Res 2009; 8: 3222-3338.
26. Rubbo H, Radi R: Protein and lipid nitration: role in redox signaling and injury. Biochim Biophys Acta 2008; 1780: 1318-1324.
27. Lee JR, Kim JK, Lee SJ, Kim KP: Role of protein tyrosine nitration in neurodegenerative diseases and atherosclerosis. Arch Pharm Res 2009; 32: 1109-1118.
28. Mohiuddin I, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C: Nitrotyrosine and chlorotyrosine: clinical significance and biological functions in the vascular system. J Surg Res 2006; 133: 143-149. (Pubitemid 43765765)
29. Turko IV, Murad F: Protein nitration in cardiovascular diseases. Pharmacol Rev 2002; 54: 619-634. (Pubitemid 35351199)
30. Ryberg H, Caidahl K: Chromatographic and mass spectrophotometric methods for quantitative determination of 3-nitrotyrosine in biological samples and their application to human samples. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851: 160-171. (Pubitemid 46720146)
31. Hurst JK: Whence nitrotyrosine? J Clin Invest 2002; 109: 1287-1289. (Pubitemid 34546892)
32. Baldus S, Eiserich JP, Brennan ML, Jackson RM, Alexander CB, Freeman BA: Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radic Biol Med 2002; 33: 1010-1019. (Pubitemid 35284038)
33. Ischiropulos H: Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys 1998; 356: 1-11.
34. Mitrogianni Z, Barbouti A, Galaris D, Siamopoulos KC: Tyrosine nitration in plasma proteins from patients undergoing hemodialysis. Amer J Kidney Diseases 2004; 44: 286-292. (Pubitemid 38962557)
35. Massy ZA, Borderie D, Nguyen-Khoa T, Drüeke TB: Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 153-157. (Pubitemid 36104492)
36. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
37. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B: Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 1993; 121: 257-262. (Pubitemid 23073132)
38. Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58: 2571-2578.
39. Witko-Sarsat V, Friedlander M, Khoa TN, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T, Descamps-Latscha B: Advanced oxidation protein products as a novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532. (Pubitemid 28397070)
40. Koçak H, Gumuslu S, Sahin E, Ceken K, Gocmen YA, Yakupoglu G, Ersoy FF, Tuncer M: Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Nephrology 2009; 14: 273-280.
41. Boulanger E, Moranne O, Wautier MP, Witko-Sarsat V, Descamps-Latscha B, Kandoussi A, Grossin N, Wautier JL: Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study. Perit Dial Int 2005; 26: 207-212. (Pubitemid 44336173)
42. Agalou S, Ahmed N, Babei-Jadidi RB, Dawnay A, Thornalley PJ: Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005; 16: 1471-1485. (Pubitemid 41716533)
43. Müller-Krebs S, Kihm LP, Zeier B, Gross ML, Deppisch R, Wieslander A, Henle T, Penndorf I, Oh J, Raiser J, Nawroth P, Zeier M, Schwenger V: Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure. Eur J Clin Invest 2008; 38: 296-305. (Pubitemid 351489911)
44. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E: Glucose degradation products in PD fluids. Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63: 298-305. (Pubitemid 35463934)